VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Business Services

NeoGenomics Executive Compensation (FY25)

NEO · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Tony Zook
Median of the other named officers
$3,869,191
6 officers, excluding the chief executive
Latest say-on-pay support
=
May 21, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The NeoGenomics brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): May 22, 2026
13 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
NeoGenomics brief$500Get the executive brief
Velarion Intel, one year, every company
445 figures on this page: 436 cited to the filing that reported them, 9 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: Christopher Smith → Tony Zook
CEO pay ratio: 117:1 → 93:1 (20.5% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is NeoGenomics' chief executive and what were they paid?
Tony Zook, Director and Chief Executive Officer, received $9,127,092 in total compensation for fiscal 2025.
What was NeoGenomics' say-on-pay result?
The say-on-pay proposal drew 83.2% support at the meeting held May 21, 2026 for fiscal 2025.
Which companies are in NeoGenomics' peer group?
Companies named in the disclosed peer group include 10x Genomics, Inc., Adaptive Biotechnologies Corporation, AtriCure, Inc., CareDx, Inc. and Emergent BioSolutions, Inc., among others.
What is NeoGenomics' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 93:1, against median employee compensation of $101,144.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Smith
Director and Chief Executive Officer
◇—◇◇◇—◇◇
Vishal Sikri
President, Advanced Diagnostics
◇◇◇◇◇—◇◇
Jeffrey Sherman
Chief Financial Officer
◇◇◇◇———◇
Warren Stone
President, Clinical Services
◇◇◇◇———◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Smith
Director and Chief Executive Officer
◇—◇◇◇—◇◇
Melody Harris
President, Enterprise Operations
◇—◇◇◇—◇◇
Jeffrey Sherman
Chief Financial Officer
◇—◇◇◇—◇◇
Warren Stone
President, Clinical Services
◇—◇◇◇—◇◇
Vishal Sikri
President, Advanced Diagnostics
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Smith
Director and Chief Executive Officer
◇—◇◇◇—◇◇
Jeffrey Sherman
Chief Financial Officer
◇—◇◇◇—◇◇
Warren Stone
President & Chief Operating Officer
◇—◇◇◇—◇◇
Melody Harris
Chief Operations Officer and President, Oncology Data Solutions
◇—◇◇◇—◇◇
Vishal Sikri
President, Advanced Diagnostics
◇—◇◇——◇◇
Alicia Olivo
Executive Vice President, General Counsel & Business Development
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Tony Zook
Director and Chief Executive Officer
◇—◇◇◇—◇◇
Warren Stone
President and Chief Operating Officer
◇◇◇◇◇—◇◇
Jeffrey Sherman
Chief Financial Officer
◇◇◇◇◇—◇◇
Christopher Smith
Former Director and Former Chief Executive Officer
Departed during or after this year
◇—◇—◇—◇◇
Melody Harris
Former Chief Operations Officer and President, Oncology Data Solutions
Departed during or after this year
◇◇◇◇——◇◇
Alicia Olivo
Executive Vice President, General Counsel & Business Development
◇◇◇◇◇—◇◇
Gary Passman
Chief Culture Officer
◇◇◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Alicia OlivoPSU◇—◇◇◇—◇
Alicia OlivoRSU◇——◇——◇
Alicia OlivoOPTION◇——◇—◇◇
Christopher SmithPSU◇—◇◇◇—◇
Gary PassmanPSU◇—◇◇◇—◇
Gary PassmanOPTION◇——◇—◇◇
Gary PassmanRSU◇——◇——◇
Jeffrey ShermanPSU◇—◇◇◇—◇
Jeffrey ShermanOPTION◇——◇—◇◇
Jeffrey ShermanRSU◇——◇——◇
Melody HarrisPSU◇——◇——◇
Melody HarrisRSU◇——◇——◇
Tony ZookPSU◇—◇◇◇—◇
Tony ZookOPTION◇——◇—◇◇
Warren StonePSU◇—◇◇◇—◇
Warren StoneOPTION◇——◇—◇◇
Warren StoneRSU◇——◇——◇
Warren StoneRSU◇——◇——◇
Warren StoneOPTION◇——◇—◇◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Jeffrey ShermanOption◇—◇2/21/35
RSU◇◇——
Option◇—◇12/05/29
RSU◇◇——
Option◇—◇2/23/34
PSU◇◇——
RSU◇◇——
Option◇—◇5/11/30
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Warren StoneOption◇—◇2/21/35
Option◇—◇4/01/35
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇12/01/29
Option◇—◇2/23/34
RSU◇◇——
PSU◇◇——
Option◇—◇5/02/34
Option◇—◇5/11/30
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
Melody HarrisRSU◇◇——
Alicia OlivoOption◇—◇2/21/35
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇2/23/34
Option◇—◇9/01/29
RSU◇◇——
PSU◇◇——
Option◇—◇5/11/30
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇5/01/29
RSU◇◇——
Gary PassmanOption◇—◇2/21/35
RSU◇◇——
RSU◇◇——
Option◇—◇2/07/30
Option◇—◇2/23/34
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Alicia Olivo
Executive Vice President, General Counsel & Business Development · Employment agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇
Christopher Smith
Former Director and Former Chief Executive Officer · Employment agreement
Severance multiple◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇
Gary Passman
Chief Culture Officer · Employment agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Clawback◇
Jeffrey Sherman
Chief Financial Officer · Employment agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇
Melody Harris
Former Chief Operations Officer and President, Oncology Data Solutions · Employment agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Clawback◇
Tony Zook
Director and Chief Executive Officer · Employment agreement
Severance multiple◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Warren Stone
President and Chief Operating Officer · Employment agreement
Severance multiple◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Dr. Alison Hannah
◇◇◇———◇
Lynn Tetrault
Board chair
◇◇◇———◇
Michael Kelly
◇◇◇———◇
David Perez
◇◇◇———◇
Dr. Neil Gunn
◇◇◇———◇
Felicia Williams
◇◇◇———◇
Stephen Kanovsky
◇◇◇———◇
Elizabeth Floegel
◇◇◇———◇
Dr. Marjorie Green
◇◇◇———◇
Anthony P. Zook
◇—————◇
Jack Kenny served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 10x Genomics, Inc. TXG
  • Adaptive Biotechnologies Corporation ADPT
  • AtriCure, Inc. ATRC
  • CareDx, Inc. CDNA
  • Emergent BioSolutions, Inc. EBS
  • Exact Sciences Corporation EXAS
  • Fulgent Genetics, Inc. FLGT
  • Guardant Health, Inc. GH
  • iRhythm Technologies, Inc. IRTC
  • Maravai Life Sciences Holdings, Inc. MRVI
  • Medpace Holdings, Inc. MEDP
  • Myriad Genetics, Inc. MYGN
  • Natera, Inc. NTRA
  • OPKO Health, Inc. OPK
  • QuidelOrtho Corporation QDEL
  • Veracyte, Inc. VCYT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 21, 2026=◇◇◇
2024May 22, 2025=◇◇◇
2023May 23, 2024=◇◇◇
2022May 25, 2023=◇◇◇
2021June 2, 2022=◇◇◇
2020May 27, 2021=◇◇◇
2019May 28, 2020=◇◇◇
2018June 6, 2019=◇◇◇
2015June 7, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Tony Zook (Director and Chief Executive Officer), FY2025 total compensation $9,127,092 (base salary $601,539) [exec_comp, SEC accession 0001077183-26-000014, filed 2026-04-06]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when NeoGenomics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact NeoGenomics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where NeoGenomics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether NeoGenomics' disclosed peer group is defensible, who names NeoGenomics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
445 figures on this page: 436 cited to the filing that reported them, 9 calculated from figures it prints.
436 cited to the filing
9 calculated from the filing

Documents cited

  1. 0001628280-26-037735
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001077183-26-000014
    Chief Executive Officer Pay Ratio · Grants of Plan-Based Awards · Independent Director Compensation Tables · MEMBERS OF THE CULTURE AND COMPENSATION COMMITTEE · and 3 more sections
  3. 0001077183-25-000109
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001077183-25-000068
    Summary Compensation Table
  5. 0001077183-24-000081
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001077183-24-000042
    Summary Compensation Table
  7. 0001077183-23-000068
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001077183-22-000095
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001077183-22-000017
    Employment Agreement
  10. 0001077183-21-000137
  11. 0001077183-20-000137
  12. 0001077183-19-000114
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001564590-16-020355
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “NeoGenomics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/NEO (accessed 2026).
Short form: data: Velarion

The NeoGenomics brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about NeoGenomics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Business Services rankings

Chief executive pay — Business ServicesCEO pay ratio — Business ServicesSay-on-pay support — Business Services

Peers NeoGenomics discloses

The companies named in NEO's own disclosed peer group.

10x Genomics, Inc.Adaptive Biotechnologies CorporationAtriCure, Inc.CareDx, Inc.Emergent BioSolutions, Inc.Exact Sciences CorporationFulgent Genetics, Inc.Guardant Health, Inc.iRhythm Technologies, Inc.Maravai Life Sciences Holdings, Inc.Medpace Holdings, Inc.Myriad Genetics, Inc.Natera, Inc.OPKO Health, Inc.QuidelOrtho CorporationVeracyte, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy